Pink Sheet senior writers Derrick Gingery and Sarah Karlin-Smith, senior editors Brenda Sandburg and Sue Sutter, and Executive Editor Nielsen Hobbs discuss the questions that emerged from two US Food and Drug Administration advisory committee meetings on RSV vaccines, Eli Lilly and Company’s plan to lower insulin prices, a new definition that could be added to the Orphan Drug Act and the departure of Billy Dunn as director of the FDA’s Office of Neuroscience.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?